Dementia is a syndrome caused by multiple diseases and injuries that progressively impair memory, thinking, and the ability to perform daily activities. Alzheimer disease is the most common form, accounting for an estimated 60-70% of cases. Dementia is a major cause of disability and dependency in older adults worldwide.
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.
An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
A preclinical study shows that the anti-epileptic drug levetiracetam can prevent the formation of amyloid-beta 42 in neurons by modulating synaptic vesicle recycling. Analysis of patient records indicates a modest delay in cognitive decline among Alzheimer's patients taking the drug, suggesting potential for very early preventive use.
A study finds that white matter disease detected on CT scans signals a higher risk for stroke or dementia compared to MRI-only findings. CT-detected WMD may represent more advanced cerebrovascular injury, highlighting the need for modality-specific interpretation of incidentally discovered brain abnormalities.
Two recent studies advance Alzheimer's research: one finds combining anti-amyloid antibodies with natural compounds improves efficacy and safety, while another maps a molecular cascade that could reveal new therapeutic targets. The combination therapy study used aducanumab, lecanemab, resveratrol, and curcumin. The molecular study identified gene expression networks and proposed a two-stage disease model.
Australia's Medical Research Future Fund is investing billions across multiple health research areas, including $100 million for arthritis research over 10 years, AU$22.9 million for dementia projects, and $436 million in 209 grants for Indigenous health research since 2017.
Advances in precision mental health research include TMS findings published in Nature Molecular Psychiatry showing targeted brain stimulation can address specific depression and anxiety symptoms, the launch of the three-year GlobalMinds NHS genomic study analyzing 49,000 DNA samples, and the new $1 million Wellcome Prize for Mental Health Science.
Studies linked better overall brain health, higher midlife vitamin D levels and lifelong intellectual activity with lower Alzheimer’s-related vulnerability. Findings included lower tau pathology, delayed mild cognitive impairment and dementia onset, and higher cognitive resilience.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778277 |
Personalized Sensory Stimulation: Urban and Rural Dementia Care |
NOT_YET_RECRUITING | NA |
| NCT07775833 |
Study Protocol: The Efficacy of Mushroom to Reduce Cognitive Decline in At-Risk Middle-aged Adults and Young-olds Living in the Community |
RECRUITING | NA |
| NCT07773493 |
A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement |
NOT_YET_RECRUITING | NA |
| NCT07763392 |
Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the Lifespan |
RECRUITING | |
| NCT07758738 |
Primary Care Screening and Intervention for Patients With Dementia and Caregivers |
NOT_YET_RECRUITING | NA |
| NCT07758660 |
Alzheimer's Disease Research Center (ADRC) PET Component Study |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07757178 |
Lived Experience Narratives in Dementia |
RECRUITING | NA |
| NCT07755631 |
The BASIC-S Feasibility Study for Vascular Risk Reduction |
NOT_YET_RECRUITING | NA |
| NCT07748013 |
Impact of Harp Therapy on Behavioral Disorders in Nursing Home Residents With Neurodegenerative Disease (ARPE) |
COMPLETED | |
| NCT07742189 |
Medication Collaboration Feasibility Study |
RECRUITING | NA |
